Abstract
Bladder cancer is common and one of the most expensive cancers to treat.1 The high rate of local recurrence after transurethral resection has led to frequent cystoscopies for surveillance and various treatments to prevent tumour recurrence. Although both new tumours (second primaries) and inadequately treated disease contribute to the recurrence of bladder cancer, molecular data suggest that most recurrences relate to failures of definitive treatment.2 Adjuvant intravesical chemotherapy and immunotherapy—often with mitomycin and BCG, respectively—have been the mainstays of these efforts.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
